Search results for "Adjuvant"

showing 10 items of 733 documents

Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral …

2018

INTRODUCTION: The mainstay of management for locally advanced rectal cancer is chemoradiotherapy followed by surgical resection. Following chemoradiotherapy, a complete response may be detected clinically and radiologically (cCR) prior to surgery or pathologically after surgery (pCR). We aim to report the overall complete pathological response (pCR) rate and the reliability of detecting a cCR by conventional pre-operative imaging.METHODS: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 audit was performed. Patients treated by elective rectal resection were included. A pCR was defined as a ypT0 N0 EMVI negative primary tumour; a partial response represented any r…

MaleColorectal cancerdeferral of surgery; neoadjuvant therapy; pathology; radiology; rectal cancer; Rectal surgery; surgical oncology; Gastroenterology0302 clinical medicineProspective StudiesProspective cohort studyComplete responseMedical Auditintegumentary systemIncidence (epidemiology)IncidenceRemission InductionGastroenterologyMiddle AgedMagnetic Resonance ImagingPeer reviewEuropeTreatment Outcomedeferral of surgeryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisPreoperative Period030211 gastroenterology & hepatologyFemaleAdultmedicine.medical_specialtyRectal surgeryNO03 medical and health sciencessurgical oncologymedicineHumansneoadjuvant therapyIntensive care medicineDeferralrectal cancerPathologicalResponse Evaluation Criteria in Solid TumorsAgedNeoplasm Stagingta3126business.industryRectal NeoplasmsReproducibility of ResultsChemoradiotherapy Adjuvantmedicine.diseaseradiologyRectal Neoplasms/diagnostic imagingpathologyNeoplasm Staging/methodsbusiness
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Allopurinol has Immunomodulating Activity following Topical and Systemic Application in Experimental Autoimmune Uveitis

2001

PurposeAllopurinol has beneficial effects in the systemic treatment of lens-induced uveitis and experimental autoimmune uveitis (EAU). This is believed to be due to a reduction of oxidative tissue damage through its dose-dependent free radical scavenging ability, and to an immunomodulating effect. The purpose of this study was to demonstrate the immunological effects on the IgG-antibody repertoire in EAU after topical and systemic allopurinol and steroids.MethodsWe assigned 43 male Lewis rats to 6 different groups: healthy rats (BASE, n=3), EAU without therapy (CTRL, n=9); systemic treatment with allopurinol (ALSYS, n=9, 50 mg/kg body wt.i.v., given every three days for two weeks), topical …

MaleDrugmedicine.medical_specialtyAdministration TopicalAllopurinolmedicine.medical_treatmentmedia_common.quotation_subjectBlotting WesternAllopurinol hypersensitivity syndromeAllopurinol030204 cardiovascular system & hematologyPharmacologyAutoantigens030226 pharmacology & pharmacyAutoimmune DiseasesUveitis03 medical and health sciences0302 clinical medicineAdjuvants ImmunologicInternal medicinemedicineAnimalsGlucocorticoidsAutoantibodiesmedia_commonAutoimmune diseaseChemotherapybusiness.industryAutoantibodyFree Radical ScavengersGeneral Medicinemedicine.diseaseRatsDisease Models AnimalOphthalmologyEndocrinologyMethylprednisoloneRats Inbred LewImmunoglobulin GInjections IntravenousElectrophoresis Polyacrylamide GelbusinessUveitismedicine.drugEuropean Journal of Ophthalmology
researchProduct

Treatment of experimental autoimmune encephalomyelitis with adenylate deaminase from Penicillium lanoso-viride.

2000

The effect of intramuscularly administered immunomodulator, adenylate deaminase (E.C. 3.5.4.6), from Penicillium lanoso-viride on the clinical score of acute experimental autoimmune encephalomyelitis (EAE), a T cell-mediated autoimmune disease, was examined by inoculation of guinea pigs with rabbit brain and spinal cord homogenate (encephalitogen) and complete Freund's adjuvant. Adenylate deaminase (ADA) was effective in delaying the onset of clinical disease. ADA inhibited the severity of EAE. There was a significant decrease in clinical signs. A decrease in the number of morbid and dead animals was observed. Of ADA treated animals, 50-80% developed no clinical manifestations of EAE. The o…

MaleEncephalomyelitis Autoimmune ExperimentalEncephalomyelitisImmunologyGuinea PigsCross Reactionsmedicine.disease_causeInjections IntramuscularAutoimmunityAMP DeaminaseMiceBlood serumAdjuvants Immunologicimmune system diseasesImmunology and AllergyMedicineAnimalsHypersensitivity DelayedComplement ActivationSkin TestsAutoimmune diseaseMice Inbred BALB Cbiologybusiness.industryMultiple sclerosisExperimental autoimmune encephalomyelitisPenicilliumBrainAMP deaminasemedicine.diseaseSpinal CordImmunologybiology.proteinFemaleImmunizationRabbitsAntibodybusiness2'3'-Cyclic-Nucleotide PhosphodiesterasesJournal of autoimmunity
researchProduct

The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients.

1996

Haemodialysis patients often fail to respond to hepatitis B vaccination. In this pilot study, 15 patients previously non-responsive to at least three 40 micrograms doses of hepatitis B vaccine were given 0.5, 5 or 10 micrograms kg-1 granulocyte-macrophage colony-stimulating factor (GM-CSF) subcutaneously 24 h prior to booster vaccination with a hepatitis B vaccine. Seven of the 15 patients developed antibody to hepatitis B surface antigen (HBsAb) (35-7240 IU L-1) upon initial vaccination with GM-CSF and two of four individuals responded with low HBsAb titres of 15 and 60 IU L-1 when revaccinated with hepatitis B surface antigen (HBsAg) and twice the dose of GM-CSF. The application of GM-CSF…

MaleHBsAgHepatitis B vaccinemedicine.medical_treatmentmedicine.disease_causeAdjuvants ImmunologicRenal DialysisVirologyMedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAdverse effectAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryGranulocyte-Macrophage Colony-Stimulating FactorImmunosuppressionHepatitis BMiddle Agedmedicine.diseaseHepatitis BVaccinationInfectious DiseasesImmunologybiology.proteinFemaleAntibodyHypotensionbusinessJournal of viral hepatitis
researchProduct

Solitary splenic metastasis from nasopharyngeal carcinoma: a case report and systematic review of the literature

2016

Background: Solitary splenic metastases are a rare occurrence, and the nasopharyngeal carcinoma represents one of the most uncommon primary sources. The present study aimed to describe a rare case of a solitary single splenic metastasis from nasopharyngeal carcinoma and to assess the number of cases of isolated nasopharyngeal carcinoma metastases to the spleen reported in the literature. Main body: We describe the case of a 56-year-old man with a history of nasopharyngeal carcinoma and complete remission after chemo-radiotherapy. Three months after complete remission, positron emission tomography/ computed tomography scan revealed a hypermetabolic splenic lesion without increased metabolic …

MaleHerpesvirus 4 HumanPathologymedicine.medical_specialtySplenic metastasisBiopsymedicine.medical_treatmentSplenectomyNasopharyngeal neoplasmSplenic metastasis Nasopharyngeal carcinoma Systematic reviewSplenic NeoplasmReview03 medical and health sciencesRare Diseases0302 clinical medicineSurgical oncologyNasopharynxPositron Emission Tomography Computed TomographyBiopsymedicineCarcinomaHumansNeoadjuvant therapyNeoplasm StagingNasopharyngeal Carcinomamedicine.diagnostic_testbusiness.industrySplenic NeoplasmsCarcinomaNasopharyngeal NeoplasmsChemoradiotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingNeoadjuvant TherapySettore MED/18 - Chirurgia GeneraleTreatment OutcomeOncologyNasopharyngeal carcinomaLymphatic Metastasis030220 oncology & carcinogenesisSystematic reviewSplenectomyLaparoscopy030211 gastroenterology & hepatologySurgerybusinessWorld Journal of Surgical Oncology
researchProduct

Arthus type inflammation with rat immunoglobulins.

1971

Etude comparative des proprietes biologiques des anticorps IgM, IgG1 et IgG2 du rat. Les resultats montrent que le pouvoir agglutinant et lytique des anticorps IgM est respectivement 37 et 100 fois superieur a celui des deux classes d'anticorps IgG. Par contre, en ce qui concerne le phenomene d'Arthus, les anticorps IgM sont moins actifs que les anticorps IgG, si les rapports sont exprimes en poids. Si l'on calcule les rapports par nombre de molecules, les anticorps IgM sont aussi, dans ce cas, plus actifs que les IgG.

MaleImmunodiffusioneducationFreund's AdjuvantImmunoglobulinsInflammationHemolysisChromatography DEAE-CelluloseAntigen-Antibody ReactionsCellular and Molecular NeurosciencemedicineArthus ReactionAnimalsMolecular BiologyPharmacologybiologyChemistryImmune SeraSerum Albumin BovineCell BiologyHemagglutination TestsMolecular biologyRatsMolecular WeightImmunoglobulin Gbiology.proteinMolecular MedicineImmunizationmedicine.symptomAntibodyExperientia
researchProduct

EARLY CHOLINE LEVELS FROM 3-TESLA MR SPECTROSCOPY AFTER EXCLUSIVE RADIATION THERAPY IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER ARE PREDICT…

2011

International audience; Abstract: Purpose: To investigate the time course response of prostate metabolism to irradiation using magnetic resonance spectroscopy (MRS) at 3-month intervals and its impact on biochemical control. Methods and Materials: Between January 2008 and April 2010, 24 patients with localized prostate cancer were prospectively enrolled in the Evaluation of the Response to Irradiation with MR Spectroscopy (ERIS) trial. All the patients had been treated with intensity-modulated radiation therapy with or without long-term adjuvant hormonal therapy (LTHT) and underwent 3-T MRS and prostate-specific antigen (PSA) assays at baseline and every 3 months thereafter up to 12 months.…

MaleIn vivo magnetic resonance spectroscopyCancer ResearchTime Factorsmedicine.medical_treatmentCholine030218 nuclear medicine & medical imagingchemistry.chemical_compoundProstate cancer0302 clinical medicineProstateCholineProspective StudiesProspective cohort studyProstate cancerRadiation[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingProstateOrgan SizeMiddle AgedTumor Burdenmedicine.anatomical_structureOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPredictive value of testsHormonal therapyResponse monitoringmedicine.medical_specialtyUrologyCitric Acid03 medical and health sciencesBody WaterPredictive Value of TestsMagnetic resonance spectroscopymedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingAgedbusiness.industryProstatic NeoplasmsAndrogen AntagonistsProstate-Specific Antigenmedicine.diseaseRadiation therapychemistryRadiotherapy Intensity-Modulated3 TeslabusinessNuclear medicine
researchProduct

E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial.

2008

Purpose: To test the expanded polytetrafluoroethylene (ePTFE) as a new adjuvant in trabeculectomy. Methods: Consecutive glaucoma surgical inpatients were observed at the Department of Ophthalmology of Palermo University. Sixty patients (60 eyes) were randomly assigned to undergo trabeculectomy (T), trabeculectomy with mitomycin-C (TMMC), with ePTFE (TG) or with mitomycin-C and ePTFE (TGMMC). Postoperative visits were scheduled at 24 hr, 7 days, 1, 3, 6, 12, 18 and 24 months. Complete success and qualified success were assessed at two target intraocular pressure (IOP) levels – £21 and £17 mmHg – by Kaplan–Meier curves. Results: The postoperative IOP reduction was significant (P < 0.01) at th…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresmedicine.medical_treatmentMitomycinGlaucomaOcular HypotensionTrabeculectomyKaplan-Meier Estimatelaw.inventionRandomized controlled triallawpenetrating glaucoma surgerymedicineGlaucoma surgeryTrabeculectomyHumansPostoperative PeriodSurvival ratePolytetrafluoroethyleneIntraocular PressureE-PTFE (Gore-Tex)implantAgedDose-Response Relationship Drugbusiness.industryMitomycin CGlaucomaGeneral MedicineProstheses and ImplantsMiddle Agedmedicine.diseaserandomized clinical trialSurgerylow-dosage mitomycin-Cpenetrating glaucoma surgery; E-PTFE (Gore-Tex)implant; low-dosage mitomycin-C; randomized clinical trialOphthalmologyChemotherapy AdjuvantAnesthesiaFemaleImplantbusiness
researchProduct

Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial

2011

AIM: To verify the safety and efficacy of Ologen (OLO) implant as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy. METHODS: This was a prospective randomized clinical trial with a 24-month follow-up. Forty glaucoma patients (40 eyes) were assigned to trabeculectomy with MMC or OLO. Primary outcome includes target IOP at ≤21, ≤17, and ≤15 mm Hg; complete (target IOP without medications), and qualified success (target IOP regardless of medications). Secondary outcomes include bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain optical coherence tomography (SD-OCT) examination; number of glaucoma medications; and frequency of postoperative…

MaleIntraocular pressuremedicine.medical_specialtymedicine.medical_treatmentMitomycinGlaucomaTrabeculectomyMatrix (biology)law.inventionRandomized controlled triallawAbsorbable ImplantsmedicineTrabeculectomyHumansProspective StudiesIntraocular PressureAgedGlycosaminoglycansIntraoperative CareSettore MED/30 - Malattie Apparato Visivobusiness.industryMitomycin CGlaucomaProstheses and ImplantsMiddle AgedOlogen MMC trabeculectomymedicine.diseaseSurgeryOphthalmologyCross-Linking ReagentsClinical StudyFemaleImplantCollagenbusinessAdjuvantTomography Optical Coherence
researchProduct